Extended Data Fig. 7: Agreement of mCARMEN RVP patient and contrived sample testing in CLIA-certified laboratory. | Nature Medicine

Extended Data Fig. 7: Agreement of mCARMEN RVP patient and contrived sample testing in CLIA-certified laboratory.

From: Multiplexed CRISPR-based microfluidic platform for clinical testing of respiratory viruses and identification of SARS-CoV-2 variants

Extended Data Fig. 7

a, Workflow of patient specimen evaluation. Patient specimens were originally tested by either Cepheid and BioFire RP2.0/2.1. We tested these specimens by both RVP and BioFire RP2.0/2.1 or TaqPath COVID-19 Combo Kit then a subset of these specimens were subjected to unbiased NGS. b, Concordance between RVP and either Cepheid or BioFire RP2.0/2.1 for 166 patient specimens. Positive and negative percent agreements are shown in parenthesis. c, Concordance between RVP and NGS for 30 out of the 166 patient specimens. d, Concordance of contrived samples to RVP. Contrived samples were prepared by spiking viral seed stock, genomic RNA, or synthetic RNA into negative patient specimens.

Back to article page